Metabolic Dysfunction-associated Steatotic Liver Disease in Klinefelter Syndrome: High Prevalence Uncovers an Unmet Need
Open Access
- 29 August 2025
- journal article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (3) , e868-e876
Abstract
Context: Klinefelter syndrome (KS) has a higher propensity for metabolic disorders and increased cardiovascular risk. The prevalence and the characteristics of metabolic dysfunction-associated steatotic liver disease (MASLD) have not been described yet in KS. Objective: We aim to study the relationship between hypogonadism, liver diseases, and cardiovascular risk using a unique KS model. Methods: This cross-sectional study included 82 patients with KS. Data collected included anthropometric measurements, hormonal and liver function parameters, and abdominal ultrasound findings. In a subgroup of 46 patients, hepatic steatosis was evaluated using the control attenuation parameter (CAP) via FibroScan. Cardiovascular risk was assessed using Score2 and Score2-Diabetes. Results: The prevalence of MASLD in patients with KS was 45.1%. Patients with MASLD were significantly older (P < .001), had higher body mass index (P < .001), waist circumference (P < .001), and a greater prevalence of diabetes (P = .004). In multivariable logistic regression analysis, metabolic syndrome was the only independent predictor of MASLD. For FibroScan/CAP evaluation, the median liver stiffness (KPa) was 4.7. The median CAP value was 244.0 ± 59.4 dB/m. Correlation analysis revealed a significant negative relationship between CAP and IGF-1 (P ≤ .001). In contrast, CAP was positively correlated with triglycerides (P = .020), insulin resistance index (P = .017), waist circumference (P < .001), and body mass index (P ≤ .001). Cardiovascular risk showed no significant differences between the MASLD and non-MASLD groups. Conclusion: This first study highlights substantial MASLD prevalence in patients with KS (45.1%). Metabolic syndrome is the major independent predictor of MASLD with a negative correlation between CAP and IGF-1. Early identification of MASLD is crucial to address the elevated risk of metabolic complications in this vulnerable population.Keywords
Funding Information
- PRIN: PROGETTI DI RICERCA DI RILEVANTE INTERESSE NAZIONALE—Bando 2022 (2022NCL5JE)
This publication has 43 references indexed in Scilit:
- EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive SummaryDiabetologia, 2024
- Mild liver dysfunction in Klinefelter syndrome is associated with abdominal obesity and elevated lipids but not testosterone treatmentJournal of Endocrinological Investigation, 2024
- Hypogonadism and nonalcoholic fatty liver diseaseEndocrine, 2024
- Longitudinal Outcomes Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis of 129 StudiesClinical Gastroenterology and Hepatology, 2023
- Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistanceJournal of Hepatology, 2023
- Association of sex hormones with hepatic steatosis in men with chronic hepatitis BDigestive and Liver Disease, 2022
- Klinefelter syndrome, insulin resistance, metabolic syndrome, and diabetes: review of literature and clinical perspectivesEndocrine, 2018
- Klinefelter syndrome: cardiovascular abnormalities and metabolic disordersJournal of Endocrinological Investigation, 2017
- Klinefelter syndrome (KS): genetics, clinical phenotype and hypogonadismJournal of Endocrinological Investigation, 2016
- Cardiovascular abnormalities in Klinefelter SyndromeInternational Journal of Cardiology, 2013